secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001655759-24-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas/Pfizer report updated Phase 1b combo data of vepdegestrant + palbociclib; consistent with prior
--------------------------------------------------------------------------------

- Clinical benefit rate 63% across all doses; at RP3D 200 mg, CBR 67%; ORR 42% overall, 53% at 200 mg.
- Median progression-free survival 11.2 months across doses; at 200 mg, mPFS 13.9 months (95% CI: 8.1-NR).
- Median duration of response 14.6 months in 13 responders; safety consistent with prior, Grade 3/4 neutropenia 91%.
- ctDNA showed marked reduction in tumor fraction (-98.9%) after one cycle regardless of ESR1 mutation status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/0001655759-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/arvn-20240516.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer